These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33387997)

  • 1. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19).
    McCullough PA; Alexander PE; Armstrong R; Arvinte C; Bain AF; Bartlett RP; Berkowitz RL; Berry AC; Borody TJ; Brewer JH; Brufsky AM; Clarke T; Derwand R; Eck A; Eck J; Eisner RA; Fareed GC; Farella A; Fonseca SNS; Geyer CE; Gonnering RS; Graves KE; Gross KBV; Hazan S; Held KS; Hight HT; Immanuel S; Jacobs MM; Ladapo JA; Lee LH; Littell J; Lozano I; Mangat HS; Marble B; McKinnon JE; Merritt LD; Orient JM; Oskoui R; Pompan DC; Procter BC; Prodromos C; Rajter JC; Rajter JJ; Ram CVS; Rios SS; Risch HA; Robb MJA; Rutherford M; Scholz M; Singleton MM; Tumlin JA; Tyson BM; Urso RG; Victory K; Vliet EL; Wax CM; Wolkoff AG; Wooll V; Zelenko V
    Rev Cardiovasc Med; 2020 Dec; 21(4):517-530. PubMed ID: 33387997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents.
    Alexander PE; Armstrong R; Fareed G; Lotus J; Oskoui R; Prodromos C; Risch HA; Tenenbaum HC; Wax CM; Dara P; McCullough PA; Gill KK
    Med Hypotheses; 2021 Aug; 153():110622. PubMed ID: 34130113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection.
    Procter BC; Ross C; Pickard V; Smith E; Hanson C; McCullough PA
    Rev Cardiovasc Med; 2020 Dec; 21(4):611-614. PubMed ID: 33388006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection.
    McCullough PA; Kelly RJ; Ruocco G; Lerma E; Tumlin J; Wheelan KR; Katz N; Lepor NE; Vijay K; Carter H; Singh B; McCullough SP; Bhambi BK; Palazzuoli A; De Ferrari GM; Milligan GP; Safder T; Tecson KM; Wang DD; McKinnon JE; O'Neill WW; Zervos M; Risch HA
    Am J Med; 2021 Jan; 134(1):16-22. PubMed ID: 32771461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients.
    Hazan S; Dave S; Gunaratne AW; Dolai S; Clancy RL; McCullough PA; Borody TJ
    Future Microbiol; 2022 Mar; 17():339-350. PubMed ID: 35135310
    [No Abstract]   [Full Text] [Related]  

  • 7. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
    Quirch M; Lee J; Rehman S
    J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    McCullough PA
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32967849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.
    Wiersinga WJ; Rhodes A; Cheng AC; Peacock SJ; Prescott HC
    JAMA; 2020 Aug; 324(8):782-793. PubMed ID: 32648899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
    Atluri S; Manchikanti L; Hirsch JA
    Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
    Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
    Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Landscape of Heparin Therapy for COVID-19.
    Shi C; Tingting W; Li JP; Sullivan MA; Wang C; Wang H; Deng B; Zhang Y
    Carbohydr Polym; 2021 Feb; 254():117232. PubMed ID: 33357843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comment on: 'Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients'.
    Garza-Santiago E; Ortiz-Hernández A; Kammar-García A; Mancilla-Galindo J
    Future Microbiol; 2022 Nov; 17():1277-1281. PubMed ID: 36111805
    [No Abstract]   [Full Text] [Related]  

  • 17. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.